SCHEMBL8267152

SCHEMBL8267152

Cc1cc(C(=O)Nc2ccc(O)cc2)no1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.79
RAB9A P51151 7/20 0.79
ALDH1A1 P00352 6/20 0.79
TP53 P04637 2/20 0.79
GLA P06280 1/20 0.79
HTT P42858 1/20 0.79
SMN1; SMN2 Q16637 5/20 0.71
NFKB1 P19838 1/20 0.71
NFKB2 Q00653 1/20 0.71
RELA Q04206 1/20 0.71
MAPT P10636 5/20 0.63
GAA P10253 3/20 0.62
LMNA P02545 1/20 0.62
USP2 O75604 1/20 0.62
HSD17B10 Q99714 1/20 0.61
POLB P06746 1/20 0.59
AGTR1 P30556 1/20 0.58
GFER P55789 1/20 0.58
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8267173 0.93 NPC1 (0.90) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL10192186 0.89 NPC1 (1.00) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL13321363 0.87 RAB9A (0.79) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL8266861 0.86 NPC1 (0.77) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL24025328 0.85 NPC1 (0.67) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL8267150 0.85 NPC1 (0.67) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL8266868 0.85 RAB9A (0.77) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL24025350 0.84 NPC1 (0.70) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL1394901 0.84 NPC1 (0.75) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL8267289 0.83 RAB9A (1.00) NPC1RAB9AALDH1A1TP53GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210355093-A1 NOVEL COMPOUND AND APPLICATION THEREOF IN TREATING INFLAMMATION OR INFLAMMATION-RELATED DISEASES SICHUAN CENTER FOR TRANSLATIONAL MEDICINE OF TRADITIONAL CHINESE MEDICINE (CN) 2021-11-18 US disclosed
US-7291743-B2 Isoxazole derivatives and methods of treating nitric oxide mediated diseases GENEBLUE CORPORATION (US) 2007-11-06 US disclosed
US-7291743-B2 Isoxazole derivatives and methods of treating nitric oxide mediated diseases GENEBLUE CORPORATION (US) 2007-11-06 US disclosed
US-20060223873-A1 Isoxazole derivatives and methods of treating nitric oxide mediated diseases GENEBLUE CORPORATION 2006-10-05 US disclosed
US-20060223873-A1 Isoxazole derivatives and methods of treating nitric oxide mediated diseases GENEBLUE CORPORATION 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223873-A1 Isoxazole derivatives and methods of treating nitric oxide mediated diseases NOS1, NOS2, NOS3 NPC1 2018/4885RAB9A 4416/4885ALDH1A1 295/4885
US-20210355093-A1 NOVEL COMPOUND AND APPLICATION THEREOF IN TREATING INFLAMMATION OR INFLAMMATION-RELATED DISEASES PTGES2, PTGS1, PTGS2 NPC1 2661/4885RAB9A 3712/4885ALDH1A1 2283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.